Kamada (NASDAQ:KMDA) Coverage Initiated at Benchmark

Research analysts at Benchmark started coverage on shares of Kamada (NASDAQ:KMDA) in a research note issued on Friday, Marketbeat reports. The firm set a “buy” rating and a $15.00 price target on the biotechnology company’s stock. Benchmark’s price objective would indicate a potential upside of 123.21% from the company’s previous close.

Several other analysts also recently issued reports on the stock. StockNews.com raised shares of Kamada from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 13th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Kamada in a research note on Thursday, March 6th.

Kamada Price Performance

Shares of NASDAQ KMDA opened at $6.72 on Friday. The company has a market cap of $386.27 million, a P/E ratio of 24.00, a PEG ratio of 0.97 and a beta of 0.97. Kamada has a 1 year low of $4.74 and a 1 year high of $9.16. The firm has a 50-day simple moving average of $7.19 and a two-hundred day simple moving average of $6.25.

Institutional Trading of Kamada

Several institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC raised its stake in shares of Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock valued at $178,000 after acquiring an additional 1,549 shares in the last quarter. Aristides Capital LLC increased its holdings in Kamada by 12.1% during the fourth quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock valued at $387,000 after buying an additional 6,850 shares during the period. NewEdge Advisors LLC increased its holdings in Kamada by 54.2% during the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after buying an additional 8,260 shares during the period. JPMorgan Chase & Co. purchased a new position in Kamada during the fourth quarter valued at approximately $67,000. Finally, Public Employees Retirement System of Ohio purchased a new position in Kamada during the third quarter valued at approximately $77,000. Institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.